Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.
Eleven patients with severe left ventricular impairment (mean ejection fraction 24%) and moderate impairment of exercise tolerance underwent a double-blind, placebo-controlled, cross-over trial of the orally administered beta-agonist prenalterol. Exercise hemodynamics and tolerance were measured during bicycle and treadmill exercise after 2 weeks of therapy with placebo or prenalterol. Cardiac index, ejection fraction, and stroke work index were not improved and exercise duration and peak oxygen consumption were not significantly different during the two treatments. During prenalterol treatment heart rate during exercise was consistently reduced. These results show that prolonged therapy with prenalterol does not improve hemodynamics or exercise tolerance and is associated with a diminished heart rate response to exercise.
D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000328:Adult; D004311:Double-Blind Method; D004341:Drug Evaluation; D005080:Exercise Test; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011217:Practolol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011294:Prenalterol; D011897:Random Allocation; D012146:Rest; D013318:Stroke Volume / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D011294:Prenalterol; D011217:Practolol